craft-sa-dev Home  

PMC:1283364 / 2251-5482 JSONTXT 5 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T706 13-17 IN denotes Over
T707 18-19 DT denotes a
T708 20-26 NN denotes decade
T709 27-30 RB denotes ago
T711 31-34 DT denotes the
T713 35-42 NN denotes amyloid
T714 43-50 NN denotes cascade
T712 51-61 NN denotes hypothesis
T710 62-71 VBD denotes predicted
T715 72-76 IN denotes that
T717 77-86 VBN denotes increased
T718 87-93 NNS denotes levels
T719 94-96 IN denotes of
T720 97-104 NN denotes amyloid
T722 104-105 HYPH denotes -
T721 105-106 NN denotes β
T724 107-108 -LRB- denotes (
T725 108-110 NN denotes Aβ
T726 110-111 -RRB- denotes )
T723 112-119 NN denotes peptide
T716 120-124 VBP denotes lead
T727 125-127 IN denotes to
T728 128-137 JJ denotes secondary
T729 138-149 NNS denotes pathologies
T730 150-154 WDT denotes that
T732 155-165 RB denotes ultimately
T731 166-175 VBP denotes culminate
T733 176-178 IN denotes in
T734 179-182 DT denotes the
T735 183-188 NN denotes onset
T736 189-191 IN denotes of
T737 192-201 NNP denotes Alzheimer
T738 202-209 NN denotes disease
T739 210-211 -LRB- denotes (
T740 211-213 NN denotes AD
T741 213-214 -RRB- denotes )
T742 215-216 -LRB- denotes [
T743 216-217 CD denotes 1
T744 217-218 -RRB- denotes ]
T745 218-219 . denotes .
T746 219-519 sentence denotes Early support for this hypothesis came from genetic studies linking early-onset AD to mutations in the amyloid precursor protein (APP), from which Aβ is derived, and presenilins 1 and 2, which are interchangeable components of a endoprotease complex that releases Aβ from APP (for review see [2,3]).
T747 220-225 JJ denotes Early
T748 226-233 NN denotes support
T750 234-237 IN denotes for
T751 238-242 DT denotes this
T752 243-253 NN denotes hypothesis
T749 254-258 VBD denotes came
T753 259-263 IN denotes from
T754 264-271 JJ denotes genetic
T755 272-279 NNS denotes studies
T756 280-287 VBG denotes linking
T757 288-293 JJ denotes early
T759 293-294 HYPH denotes -
T758 294-299 NN denotes onset
T760 300-302 NN denotes AD
T761 303-305 IN denotes to
T762 306-315 NNS denotes mutations
T763 316-318 IN denotes in
T764 319-322 DT denotes the
T766 323-330 NN denotes amyloid
T767 331-340 NN denotes precursor
T765 341-348 NN denotes protein
T768 349-350 -LRB- denotes (
T769 350-353 NN denotes APP
T770 353-354 -RRB- denotes )
T771 354-356 , denotes ,
T772 356-360 IN denotes from
T774 361-366 WDT denotes which
T775 367-369 NN denotes Aβ
T776 370-372 VBZ denotes is
T773 373-380 VBN denotes derived
T777 380-382 , denotes ,
T778 382-385 CC denotes and
T779 386-397 NNS denotes presenilins
T780 398-399 CD denotes 1
T781 400-403 CC denotes and
T782 404-405 CD denotes 2
T783 405-407 , denotes ,
T784 407-412 WDT denotes which
T785 413-416 VBP denotes are
T786 417-432 JJ denotes interchangeable
T787 433-443 NNS denotes components
T788 444-446 IN denotes of
T789 447-448 DT denotes a
T791 449-461 NN denotes endoprotease
T790 462-469 NN denotes complex
T792 470-474 WDT denotes that
T793 475-483 VBZ denotes releases
T794 484-486 NN denotes Aβ
T795 487-491 IN denotes from
T796 492-495 NN denotes APP
T797 496-497 -LRB- denotes (
T799 497-500 IN denotes for
T800 501-507 NN denotes review
T798 508-511 VBP denotes see
T801 512-513 -LRB- denotes [
T802 513-514 CD denotes 2
T804 514-515 , denotes ,
T803 515-516 CD denotes 3
T805 516-517 -RRB- denotes ]
T806 517-518 -RRB- denotes )
T807 518-519 . denotes .
T808 519-733 sentence denotes If, as predicted, overproduction of Aβ initiates the cascade of events leading to disease, then therapeutic strategies that lower Aβ levels should either arrest or reverse the progression from peptide to dementia.
T809 520-522 IN denotes If
T811 522-524 , denotes ,
T812 524-526 IN denotes as
T813 527-536 VBN denotes predicted
T814 536-538 , denotes ,
T815 538-552 NN denotes overproduction
T816 553-555 IN denotes of
T817 556-558 NN denotes Aβ
T810 559-568 VBZ denotes initiates
T819 569-572 DT denotes the
T820 573-580 NN denotes cascade
T821 581-583 IN denotes of
T822 584-590 NNS denotes events
T823 591-598 VBG denotes leading
T824 599-601 IN denotes to
T825 602-609 NN denotes disease
T826 609-611 , denotes ,
T827 611-615 RB denotes then
T828 616-627 JJ denotes therapeutic
T829 628-638 NNS denotes strategies
T830 639-643 WDT denotes that
T831 644-649 VBP denotes lower
T832 650-652 NN denotes Aβ
T833 653-659 NNS denotes levels
T834 660-666 MD denotes should
T835 667-673 CC denotes either
T818 674-680 VB denotes arrest
T836 681-683 CC denotes or
T837 684-691 VB denotes reverse
T838 692-695 DT denotes the
T839 696-707 NN denotes progression
T840 708-712 IN denotes from
T841 713-720 NN denotes peptide
T842 721-723 IN denotes to
T843 724-732 NN denotes dementia
T844 732-733 . denotes .
T845 733-945 sentence denotes Early evidence from clinical trials of antibody-mediated clearance, one of the first Aβ-lowering approaches tested in humans, suggested that treatments designed to reduce amyloid burden may indeed be beneficial.
T846 734-739 JJ denotes Early
T847 740-748 NN denotes evidence
T849 749-753 IN denotes from
T850 754-762 JJ denotes clinical
T851 763-769 NNS denotes trials
T852 770-772 IN denotes of
T853 773-781 NN denotes antibody
T855 781-782 HYPH denotes -
T854 782-790 VBN denotes mediated
T856 791-800 NN denotes clearance
T857 800-802 , denotes ,
T858 802-805 CD denotes one
T859 806-808 IN denotes of
T860 809-812 DT denotes the
T862 813-818 JJ denotes first
T863 819-821 NN denotes Aβ
T865 821-822 HYPH denotes -
T864 822-830 VBG denotes lowering
T861 831-841 NNS denotes approaches
T866 842-848 VBN denotes tested
T867 849-851 IN denotes in
T868 852-858 NNS denotes humans
T869 858-860 , denotes ,
T848 860-869 VBD denotes suggested
T870 870-874 IN denotes that
T872 875-885 NNS denotes treatments
T873 886-894 VBN denotes designed
T874 895-897 TO denotes to
T875 898-904 VB denotes reduce
T876 905-912 NN denotes amyloid
T877 913-919 NN denotes burden
T878 920-923 MD denotes may
T879 924-930 RB denotes indeed
T871 931-933 VB denotes be
T880 934-944 JJ denotes beneficial
T881 944-945 . denotes .
T882 945-1237 sentence denotes Although the trials were halted because of adverse effects in a subset of volunteers [4,5], further analysis of several patients found evidence that amyloid pathology, and to a lesser degree cognitive function, was improved in proportion to the patient's titer of Aβ-specific antibody [6,7].
T883 946-954 IN denotes Although
T885 955-958 DT denotes the
T886 959-965 NNS denotes trials
T887 966-970 VBD denotes were
T884 971-977 VBN denotes halted
T889 978-985 IN denotes because
T890 986-988 IN denotes of
T891 989-996 JJ denotes adverse
T892 997-1004 NNS denotes effects
T893 1005-1007 IN denotes in
T894 1008-1009 DT denotes a
T895 1010-1016 NN denotes subset
T896 1017-1019 IN denotes of
T897 1020-1030 NNS denotes volunteers
T898 1031-1032 -LRB- denotes [
T900 1032-1033 CD denotes 4
T901 1033-1034 , denotes ,
T899 1034-1035 CD denotes 5
T902 1035-1036 -RRB- denotes ]
T903 1036-1038 , denotes ,
T904 1038-1045 JJ denotes further
T905 1046-1054 NN denotes analysis
T906 1055-1057 IN denotes of
T907 1058-1065 JJ denotes several
T908 1066-1074 NNS denotes patients
T888 1075-1080 VBD denotes found
T909 1081-1089 NN denotes evidence
T910 1090-1094 IN denotes that
T912 1095-1102 NN denotes amyloid
T913 1103-1112 NN denotes pathology
T914 1112-1114 , denotes ,
T915 1114-1117 CC denotes and
T916 1118-1120 IN denotes to
T918 1121-1122 DT denotes a
T920 1123-1129 JJR denotes lesser
T919 1130-1136 NN denotes degree
T921 1137-1146 JJ denotes cognitive
T917 1147-1155 NN denotes function
T922 1155-1157 , denotes ,
T923 1157-1160 VBD denotes was
T911 1161-1169 VBN denotes improved
T924 1170-1172 IN denotes in
T925 1173-1183 NN denotes proportion
T926 1184-1186 IN denotes to
T927 1187-1190 DT denotes the
T928 1191-1198 NN denotes patient
T930 1198-1200 POS denotes 's
T929 1201-1206 NN denotes titer
T931 1207-1209 IN denotes of
T932 1210-1212 NN denotes Aβ
T934 1212-1213 HYPH denotes -
T933 1213-1221 JJ denotes specific
T935 1222-1230 NN denotes antibody
T936 1231-1232 -LRB- denotes [
T938 1232-1233 CD denotes 6
T939 1233-1234 , denotes ,
T937 1234-1235 CD denotes 7
T940 1235-1236 -RRB- denotes ]
T941 1236-1237 . denotes .
T942 1237-1426 sentence denotes While this approach is promising, constant exposure to antibodies that recognize an epitope highly enriched in the brain may have unexpected side effects that will limit its long-term use.
T943 1238-1243 IN denotes While
T945 1244-1248 DT denotes this
T946 1249-1257 NN denotes approach
T944 1258-1260 VBZ denotes is
T948 1261-1270 JJ denotes promising
T949 1270-1272 , denotes ,
T950 1272-1280 JJ denotes constant
T951 1281-1289 NN denotes exposure
T952 1290-1292 IN denotes to
T953 1293-1303 NNS denotes antibodies
T954 1304-1308 WDT denotes that
T955 1309-1318 VBP denotes recognize
T956 1319-1321 DT denotes an
T957 1322-1329 NN denotes epitope
T958 1330-1336 RB denotes highly
T959 1337-1345 VBN denotes enriched
T960 1346-1348 IN denotes in
T961 1349-1352 DT denotes the
T962 1353-1358 NN denotes brain
T963 1359-1362 MD denotes may
T947 1363-1367 VB denotes have
T964 1368-1378 JJ denotes unexpected
T966 1379-1383 NN denotes side
T965 1384-1391 NNS denotes effects
T967 1392-1396 WDT denotes that
T969 1397-1401 MD denotes will
T968 1402-1407 VB denotes limit
T970 1408-1411 PRP$ denotes its
T972 1412-1416 JJ denotes long
T974 1416-1417 HYPH denotes -
T973 1417-1421 NN denotes term
T971 1422-1425 NN denotes use
T975 1425-1426 . denotes .
T976 1426-1592 sentence denotes An alternative approach that is being actively pursued for future treatment of AD seeks to lower Aβ levels by limiting its production from the precursor protein APP.
T977 1427-1429 DT denotes An
T979 1430-1441 JJ denotes alternative
T978 1442-1450 NN denotes approach
T981 1451-1455 WDT denotes that
T983 1456-1458 VBZ denotes is
T984 1459-1464 VBG denotes being
T985 1465-1473 RB denotes actively
T982 1474-1481 VBN denotes pursued
T986 1482-1485 IN denotes for
T987 1486-1492 JJ denotes future
T988 1493-1502 NN denotes treatment
T989 1503-1505 IN denotes of
T990 1506-1508 NN denotes AD
T980 1509-1514 VBZ denotes seeks
T991 1515-1517 TO denotes to
T992 1518-1523 VB denotes lower
T993 1524-1526 NN denotes Aβ
T994 1527-1533 NNS denotes levels
T995 1534-1536 IN denotes by
T996 1537-1545 VBG denotes limiting
T997 1546-1549 PRP$ denotes its
T998 1550-1560 NN denotes production
T999 1561-1565 IN denotes from
T1000 1566-1569 DT denotes the
T1002 1570-1579 NN denotes precursor
T1001 1580-1587 NN denotes protein
T1003 1588-1591 NN denotes APP
T1004 1591-1592 . denotes .
T1005 1592-1781 sentence denotes Peptide Aβ is released from APP by the action of two enzymes, the β-APP cleaving enzyme 1 (BACE1) and γ-secretase, which cleave the holoprotein at the N- and C-termini of Aβ, respectively.
T1006 1593-1600 NN denotes Peptide
T1007 1601-1603 NN denotes Aβ
T1009 1604-1606 VBZ denotes is
T1008 1607-1615 VBN denotes released
T1010 1616-1620 IN denotes from
T1011 1621-1624 NN denotes APP
T1012 1625-1627 IN denotes by
T1013 1628-1631 DT denotes the
T1014 1632-1638 NN denotes action
T1015 1639-1641 IN denotes of
T1016 1642-1645 CD denotes two
T1017 1646-1653 NNS denotes enzymes
T1018 1653-1655 , denotes ,
T1019 1655-1658 DT denotes the
T1021 1659-1660 NN denotes β
T1023 1660-1661 HYPH denotes -
T1022 1661-1664 NN denotes APP
T1024 1665-1673 VBG denotes cleaving
T1020 1674-1680 NN denotes enzyme
T1025 1681-1682 CD denotes 1
T1026 1683-1684 -LRB- denotes (
T1027 1684-1689 NN denotes BACE1
T1028 1689-1690 -RRB- denotes )
T1029 1691-1694 CC denotes and
T1030 1695-1696 SYM denotes γ
T1032 1696-1697 HYPH denotes -
T1031 1697-1706 NN denotes secretase
T1033 1706-1708 , denotes ,
T1034 1708-1713 WDT denotes which
T1035 1714-1720 VBP denotes cleave
T1036 1721-1724 DT denotes the
T1037 1725-1736 NN denotes holoprotein
T1038 1737-1739 IN denotes at
T1039 1740-1743 DT denotes the
T1041 1744-1745 NN denotes N
T1042 1745-1746 HYPH denotes -
T1043 1747-1750 CC denotes and
T1044 1751-1752 NN denotes C
T1045 1752-1753 HYPH denotes -
T1040 1753-1760 NNS denotes termini
T1046 1761-1763 IN denotes of
T1047 1764-1766 NN denotes Aβ
T1048 1766-1768 , denotes ,
T1049 1768-1780 RB denotes respectively
T1050 1780-1781 . denotes .
T1051 1781-1945 sentence denotes Several inhibitors of γ-secretase have already been produced [8,9], and small molecule inhibitors of β-APP cleaving enzyme 1 are currently being developed [10,11].
T1052 1782-1789 JJ denotes Several
T1053 1790-1800 NNS denotes inhibitors
T1055 1801-1803 IN denotes of
T1056 1804-1805 SYM denotes γ
T1058 1805-1806 HYPH denotes -
T1057 1806-1815 NN denotes secretase
T1059 1816-1820 VBP denotes have
T1060 1821-1828 RB denotes already
T1061 1829-1833 VBN denotes been
T1054 1834-1842 VBN denotes produced
T1062 1843-1844 -LRB- denotes [
T1064 1844-1845 CD denotes 8
T1065 1845-1846 , denotes ,
T1063 1846-1847 CD denotes 9
T1066 1847-1848 -RRB- denotes ]
T1067 1848-1850 , denotes ,
T1068 1850-1853 CC denotes and
T1069 1854-1859 JJ denotes small
T1071 1860-1868 NN denotes molecule
T1070 1869-1879 NNS denotes inhibitors
T1073 1880-1882 IN denotes of
T1074 1883-1884 NN denotes β
T1076 1884-1885 HYPH denotes -
T1075 1885-1888 NN denotes APP
T1077 1889-1897 VBG denotes cleaving
T1078 1898-1904 NN denotes enzyme
T1079 1905-1906 CD denotes 1
T1080 1907-1910 VBP denotes are
T1081 1911-1920 RB denotes currently
T1082 1921-1926 VBG denotes being
T1072 1927-1936 VBN denotes developed
T1083 1937-1938 -LRB- denotes [
T1085 1938-1940 CD denotes 10
T1086 1940-1941 , denotes ,
T1084 1941-1943 CD denotes 11
T1087 1943-1944 -RRB- denotes ]
T1088 1944-1945 . denotes .
T1089 1945-2057 sentence denotes The long-term effectiveness of this approach in either humans or model systems, however, has not been reported.
T1090 1946-1949 DT denotes The
T1092 1950-1954 JJ denotes long
T1094 1954-1955 HYPH denotes -
T1093 1955-1959 NN denotes term
T1091 1960-1973 NN denotes effectiveness
T1096 1974-1976 IN denotes of
T1097 1977-1981 DT denotes this
T1098 1982-1990 NN denotes approach
T1099 1991-1993 IN denotes in
T1100 1994-2000 CC denotes either
T1101 2001-2007 NNS denotes humans
T1102 2008-2010 CC denotes or
T1103 2011-2016 NN denotes model
T1104 2017-2024 NNS denotes systems
T1105 2024-2026 , denotes ,
T1106 2026-2033 RB denotes however
T1107 2033-2035 , denotes ,
T1108 2035-2038 VBZ denotes has
T1109 2039-2042 RB denotes not
T1110 2043-2047 VBN denotes been
T1095 2048-2056 VBN denotes reported
T1111 2056-2057 . denotes .
T1112 2057-2353 sentence denotes Although loss of β-APP cleaving enzyme 1 function can prevent the development of plaques in transgenic mouse models for AD (F. Laird, H. Cai, P. C. Wong, personal communication), it is not known whether the brain can clear pre-existing amyloid deposits once production of Aβ has been suppressed.
T1113 2058-2066 IN denotes Although
T1115 2067-2071 NN denotes loss
T1116 2072-2074 IN denotes of
T1117 2075-2076 NN denotes β
T1119 2076-2077 HYPH denotes -
T1118 2077-2080 NN denotes APP
T1120 2081-2089 VBG denotes cleaving
T1122 2090-2096 NN denotes enzyme
T1123 2097-2098 CD denotes 1
T1121 2099-2107 NN denotes function
T1124 2108-2111 MD denotes can
T1114 2112-2119 VB denotes prevent
T1126 2120-2123 DT denotes the
T1127 2124-2135 NN denotes development
T1128 2136-2138 IN denotes of
T1129 2139-2146 NNS denotes plaques
T1130 2147-2149 IN denotes in
T1131 2150-2160 JJ denotes transgenic
T1133 2161-2166 NN denotes mouse
T1132 2167-2173 NNS denotes models
T1134 2174-2177 IN denotes for
T1135 2178-2180 NN denotes AD
T1136 2181-2182 -LRB- denotes (
T1137 2182-2184 NNP denotes F.
T1138 2185-2190 NNP denotes Laird
T1139 2190-2192 , denotes ,
T1140 2192-2194 NNP denotes H.
T1141 2195-2198 NNP denotes Cai
T1142 2198-2200 , denotes ,
T1143 2200-2202 NNP denotes P.
T1144 2203-2205 NNP denotes C.
T1145 2206-2210 NNP denotes Wong
T1146 2210-2212 , denotes ,
T1147 2212-2220 JJ denotes personal
T1148 2221-2234 NN denotes communication
T1149 2234-2235 -RRB- denotes )
T1150 2235-2237 , denotes ,
T1151 2237-2239 PRP denotes it
T1152 2240-2242 VBZ denotes is
T1153 2243-2246 RB denotes not
T1125 2247-2252 VBN denotes known
T1154 2253-2260 IN denotes whether
T1156 2261-2264 DT denotes the
T1157 2265-2270 NN denotes brain
T1158 2271-2274 MD denotes can
T1155 2275-2280 VB denotes clear
T1159 2281-2293 JJ denotes pre-existing
T1161 2294-2301 NN denotes amyloid
T1160 2302-2310 NNS denotes deposits
T1162 2311-2315 IN denotes once
T1164 2316-2326 NN denotes production
T1165 2327-2329 IN denotes of
T1166 2330-2332 NN denotes Aβ
T1167 2333-2336 VBZ denotes has
T1168 2337-2341 VBN denotes been
T1163 2342-2352 VBN denotes suppressed
T1169 2352-2353 . denotes .
T1170 2353-2485 sentence denotes Clearly, the amyloid-lowering approach should be rigorously examined in animal models before these reagents are tested in patients.
T1171 2354-2361 RB denotes Clearly
T1173 2361-2363 , denotes ,
T1174 2363-2366 DT denotes the
T1176 2367-2374 NN denotes amyloid
T1178 2374-2375 HYPH denotes -
T1177 2375-2383 VBG denotes lowering
T1175 2384-2392 NN denotes approach
T1179 2393-2399 MD denotes should
T1180 2400-2402 VB denotes be
T1181 2403-2413 RB denotes rigorously
T1172 2414-2422 VBN denotes examined
T1182 2423-2425 IN denotes in
T1183 2426-2432 NN denotes animal
T1184 2433-2439 NNS denotes models
T1185 2440-2446 IN denotes before
T1187 2447-2452 DT denotes these
T1188 2453-2461 NNS denotes reagents
T1189 2462-2465 VBP denotes are
T1186 2466-2472 VBN denotes tested
T1190 2473-2475 IN denotes in
T1191 2476-2484 NNS denotes patients
T1192 2484-2485 . denotes .
T1193 2485-2588 sentence denotes However, the chemical secretase inhibitors most likely to reach human trials are still in development.
T1194 2486-2493 RB denotes However
T1196 2493-2495 , denotes ,
T1197 2495-2498 DT denotes the
T1199 2499-2507 JJ denotes chemical
T1200 2508-2517 NN denotes secretase
T1198 2518-2528 NNS denotes inhibitors
T1201 2529-2533 RBS denotes most
T1202 2534-2540 JJ denotes likely
T1203 2541-2543 TO denotes to
T1204 2544-2549 VB denotes reach
T1205 2550-2555 JJ denotes human
T1206 2556-2562 NNS denotes trials
T1195 2563-2566 VBP denotes are
T1207 2567-2572 RB denotes still
T1208 2573-2575 IN denotes in
T1209 2576-2587 NN denotes development
T1210 2587-2588 . denotes .
T1211 2588-2697 sentence denotes Therefore, we developed a mouse model of Alzheimer-type amyloid that expresses a controllable APP transgene.
T1212 2589-2598 RB denotes Therefore
T1214 2598-2600 , denotes ,
T1215 2600-2602 PRP denotes we
T1213 2603-2612 VBD denotes developed
T1216 2613-2614 DT denotes a
T1218 2615-2620 NN denotes mouse
T1217 2621-2626 NN denotes model
T1219 2627-2629 IN denotes of
T1220 2630-2639 NNP denotes Alzheimer
T1222 2639-2640 HYPH denotes -
T1221 2640-2644 NN denotes type
T1223 2645-2652 NN denotes amyloid
T1224 2653-2657 WDT denotes that
T1225 2658-2667 VBZ denotes expresses
T1226 2668-2669 DT denotes a
T1228 2670-2682 JJ denotes controllable
T1229 2683-2686 NN denotes APP
T1227 2687-2696 NN denotes transgene
T1230 2696-2697 . denotes .
T1231 2697-2831 sentence denotes This system, commonly known as the tet-off system, can be regulated by analogs of tetracycline administered in food or water [12,13].
T1232 2698-2702 DT denotes This
T1233 2703-2709 NN denotes system
T1235 2709-2711 , denotes ,
T1236 2711-2719 RB denotes commonly
T1237 2720-2725 VBN denotes known
T1238 2726-2728 IN denotes as
T1239 2729-2732 DT denotes the
T1241 2733-2736 NN denotes tet
T1243 2736-2737 HYPH denotes -
T1242 2737-2740 NN denotes off
T1240 2741-2747 NN denotes system
T1244 2747-2749 , denotes ,
T1245 2749-2752 MD denotes can
T1246 2753-2755 VB denotes be
T1234 2756-2765 VBN denotes regulated
T1247 2766-2768 IN denotes by
T1248 2769-2776 NNS denotes analogs
T1249 2777-2779 IN denotes of
T1250 2780-2792 NN denotes tetracycline
T1251 2793-2805 VBN denotes administered
T1252 2806-2808 IN denotes in
T1253 2809-2813 NN denotes food
T1254 2814-2816 CC denotes or
T1255 2817-2822 NN denotes water
T1256 2823-2824 -LRB- denotes [
T1258 2824-2826 CD denotes 12
T1259 2826-2827 , denotes ,
T1257 2827-2829 CD denotes 13
T1260 2829-2830 -RRB- denotes ]
T1261 2830-2831 . denotes .
T1262 2831-3231 sentence denotes The strong expression levels produced with the tet-off vectors, combined with the ability to reduce this expression by several orders of magnitude with tetracycline [14], allowed for a stringent test of how a highly effective pharmaceutical inhibitor of Aβ production would impact the progression of amyloid pathology and whether reversal of these lesions might be possible following such treatment.
T1263 2832-2835 DT denotes The
T1265 2836-2842 JJ denotes strong
T1266 2843-2853 NN denotes expression
T1264 2854-2860 NNS denotes levels
T1268 2861-2869 VBN denotes produced
T1269 2870-2874 IN denotes with
T1270 2875-2878 DT denotes the
T1272 2879-2882 NN denotes tet
T1274 2882-2883 HYPH denotes -
T1273 2883-2886 NN denotes off
T1271 2887-2894 NNS denotes vectors
T1275 2894-2896 , denotes ,
T1276 2896-2904 VBN denotes combined
T1277 2905-2909 IN denotes with
T1278 2910-2913 DT denotes the
T1279 2914-2921 NN denotes ability
T1280 2922-2924 TO denotes to
T1281 2925-2931 VB denotes reduce
T1282 2932-2936 DT denotes this
T1283 2937-2947 NN denotes expression
T1284 2948-2950 IN denotes by
T1285 2951-2958 JJ denotes several
T1286 2959-2965 NNS denotes orders
T1287 2966-2968 IN denotes of
T1288 2969-2978 NN denotes magnitude
T1289 2979-2983 IN denotes with
T1290 2984-2996 NN denotes tetracycline
T1291 2997-2998 -LRB- denotes [
T1292 2998-3000 CD denotes 14
T1293 3000-3001 -RRB- denotes ]
T1294 3001-3003 , denotes ,
T1267 3003-3010 VBD denotes allowed
T1295 3011-3014 IN denotes for
T1296 3015-3016 DT denotes a
T1298 3017-3026 JJ denotes stringent
T1297 3027-3031 NN denotes test
T1299 3032-3034 IN denotes of
T1300 3035-3038 WRB denotes how
T1302 3039-3040 DT denotes a
T1304 3041-3047 RB denotes highly
T1305 3048-3057 JJ denotes effective
T1306 3058-3072 JJ denotes pharmaceutical
T1303 3073-3082 NN denotes inhibitor
T1307 3083-3085 IN denotes of
T1308 3086-3088 NN denotes Aβ
T1309 3089-3099 NN denotes production
T1310 3100-3105 MD denotes would
T1301 3106-3112 VB denotes impact
T1311 3113-3116 DT denotes the
T1312 3117-3128 NN denotes progression
T1313 3129-3131 IN denotes of
T1314 3132-3139 NN denotes amyloid
T1315 3140-3149 NN denotes pathology
T1316 3150-3153 CC denotes and
T1317 3154-3161 IN denotes whether
T1319 3162-3170 NN denotes reversal
T1320 3171-3173 IN denotes of
T1321 3174-3179 DT denotes these
T1322 3180-3187 NNS denotes lesions
T1323 3188-3193 MD denotes might
T1318 3194-3196 VB denotes be
T1324 3197-3205 JJ denotes possible
T1325 3206-3215 VBG denotes following
T1326 3216-3220 JJ denotes such
T1327 3221-3230 NN denotes treatment
T1328 3230-3231 . denotes .
R323 T706 T707 quantmod Over,a
R324 T707 T708 nummod a,decade
R325 T708 T709 npadvmod decade,ago
R326 T709 T710 advmod ago,predicted
R327 T711 T712 det the,hypothesis
R328 T712 T710 nsubj hypothesis,predicted
R329 T713 T714 compound amyloid,cascade
R330 T714 T712 compound cascade,hypothesis
R331 T715 T716 mark that,lead
R332 T716 T710 ccomp lead,predicted
R333 T717 T718 amod increased,levels
R334 T718 T716 nsubj levels,lead
R335 T719 T718 prep of,levels
R336 T720 T721 nmod amyloid,β
R337 T721 T723 nmod β,peptide
R338 T722 T721 punct -,β
R339 T723 T719 pobj peptide,of
R340 T724 T721 punct (,β
R341 T725 T721 appos Aβ,β
R342 T726 T723 punct ),peptide
R343 T727 T716 prep to,lead
R344 T728 T729 amod secondary,pathologies
R345 T729 T727 pobj pathologies,to
R346 T730 T731 dep that,culminate
R347 T731 T729 relcl culminate,pathologies
R348 T732 T731 advmod ultimately,culminate
R349 T733 T731 prep in,culminate
R350 T734 T735 det the,onset
R351 T735 T733 pobj onset,in
R352 T736 T735 prep of,onset
R353 T737 T738 compound Alzheimer,disease
R354 T738 T736 pobj disease,of
R355 T739 T738 punct (,disease
R356 T740 T738 appos AD,disease
R357 T741 T716 punct ),lead
R358 T742 T743 punct [,1
R359 T743 T716 parataxis 1,lead
R360 T744 T743 punct ],1
R361 T745 T710 punct .,predicted
R362 T747 T748 amod Early,support
R363 T748 T749 nsubj support,came
R364 T750 T748 prep for,support
R365 T751 T752 det this,hypothesis
R366 T752 T750 pobj hypothesis,for
R367 T753 T749 prep from,came
R368 T754 T755 amod genetic,studies
R369 T755 T753 pobj studies,from
R370 T756 T755 acl linking,studies
R371 T757 T758 amod early,onset
R372 T758 T760 compound onset,AD
R373 T759 T758 punct -,onset
R374 T760 T756 dobj AD,linking
R375 T761 T756 prep to,linking
R376 T762 T761 pobj mutations,to
R377 T763 T762 prep in,mutations
R378 T764 T765 det the,protein
R379 T765 T763 pobj protein,in
R380 T766 T765 compound amyloid,protein
R381 T767 T765 compound precursor,protein
R382 T768 T765 punct (,protein
R383 T769 T765 appos APP,protein
R384 T770 T765 punct ),protein
R385 T771 T765 punct ", ",protein
R386 T772 T773 prep from,derived
R387 T773 T765 relcl derived,protein
R388 T774 T772 pobj which,from
R389 T775 T773 nsubjpass Aβ,derived
R390 T776 T773 auxpass is,derived
R391 T777 T765 punct ", ",protein
R392 T778 T765 cc and,protein
R393 T779 T780 nmod presenilins,1
R394 T780 T765 conj 1,protein
R395 T781 T780 cc and,1
R396 T782 T780 conj 2,1
R397 T783 T780 punct ", ",1
R398 T784 T785 dep which,are
R399 T785 T780 relcl are,1
R400 T786 T787 amod interchangeable,components
R401 T787 T785 attr components,are
R402 T788 T787 prep of,components
R403 T789 T790 det a,complex
R404 T790 T788 pobj complex,of
R405 T791 T790 compound endoprotease,complex
R406 T792 T793 dep that,releases
R407 T793 T790 relcl releases,complex
R408 T794 T793 dobj Aβ,releases
R409 T795 T793 prep from,releases
R410 T796 T795 pobj APP,from
R411 T797 T798 punct (,see
R412 T798 T793 parataxis see,releases
R413 T799 T798 prep for,see
R414 T800 T799 pobj review,for
R415 T801 T798 punct [,see
R416 T802 T803 nummod 2,3
R417 T803 T798 dobj 3,see
R418 T804 T803 punct ",",3
R419 T805 T798 punct ],see
R420 T806 T798 punct ),see
R421 T807 T749 punct .,came
R422 T809 T810 mark If,initiates
R423 T810 T818 advcl initiates,arrest
R424 T811 T810 punct ", ",initiates
R425 T812 T813 mark as,predicted
R426 T813 T810 advcl predicted,initiates
R427 T814 T810 punct ", ",initiates
R428 T815 T810 nsubj overproduction,initiates
R429 T816 T815 prep of,overproduction
R430 T817 T816 pobj Aβ,of
R431 T819 T820 det the,cascade
R432 T820 T810 dobj cascade,initiates
R433 T821 T820 prep of,cascade
R434 T822 T821 pobj events,of
R435 T823 T822 acl leading,events
R436 T824 T823 prep to,leading
R437 T825 T824 pobj disease,to
R438 T826 T818 punct ", ",arrest
R439 T827 T818 advmod then,arrest
R440 T828 T829 amod therapeutic,strategies
R441 T829 T818 nsubj strategies,arrest
R442 T830 T831 dep that,lower
R443 T831 T829 relcl lower,strategies
R444 T832 T833 compound Aβ,levels
R445 T833 T831 dobj levels,lower
R446 T834 T818 aux should,arrest
R447 T835 T818 preconj either,arrest
R448 T836 T818 cc or,arrest
R449 T837 T818 conj reverse,arrest
R450 T838 T839 det the,progression
R451 T839 T837 dobj progression,reverse
R452 T840 T839 prep from,progression
R453 T841 T840 pobj peptide,from
R454 T842 T840 prep to,from
R455 T843 T842 pobj dementia,to
R456 T844 T818 punct .,arrest
R457 T846 T847 amod Early,evidence
R458 T847 T848 nsubj evidence,suggested
R459 T849 T847 prep from,evidence
R460 T850 T851 amod clinical,trials
R461 T851 T849 pobj trials,from
R462 T852 T851 prep of,trials
R463 T853 T854 npadvmod antibody,mediated
R464 T854 T856 amod mediated,clearance
R465 T855 T854 punct -,mediated
R466 T856 T852 pobj clearance,of
R467 T857 T856 punct ", ",clearance
R468 T858 T856 appos one,clearance
R469 T859 T858 prep of,one
R470 T860 T861 det the,approaches
R471 T861 T859 pobj approaches,of
R472 T862 T861 amod first,approaches
R473 T863 T864 npadvmod Aβ,lowering
R474 T864 T861 amod lowering,approaches
R475 T865 T864 punct -,lowering
R476 T866 T861 acl tested,approaches
R477 T867 T866 prep in,tested
R478 T868 T867 pobj humans,in
R479 T869 T848 punct ", ",suggested
R480 T870 T871 mark that,be
R481 T871 T848 ccomp be,suggested
R482 T872 T871 nsubj treatments,be
R483 T873 T872 acl designed,treatments
R484 T874 T875 aux to,reduce
R485 T875 T873 advcl reduce,designed
R486 T876 T877 compound amyloid,burden
R487 T877 T875 dobj burden,reduce
R488 T878 T871 aux may,be
R489 T879 T871 advmod indeed,be
R490 T880 T871 acomp beneficial,be
R491 T881 T848 punct .,suggested
R492 T883 T884 mark Although,halted
R493 T884 T888 advcl halted,found
R494 T885 T886 det the,trials
R495 T886 T884 nsubjpass trials,halted
R496 T887 T884 auxpass were,halted
R497 T889 T884 prep because,halted
R498 T890 T889 pcomp of,because
R499 T891 T892 amod adverse,effects
R500 T892 T889 pobj effects,because
R501 T893 T892 prep in,effects
R502 T894 T895 det a,subset
R503 T895 T893 pobj subset,in
R504 T896 T895 prep of,subset
R505 T897 T896 pobj volunteers,of
R506 T898 T899 punct [,5
R507 T899 T884 parataxis 5,halted
R508 T900 T899 nummod 4,5
R509 T901 T899 punct ",",5
R510 T902 T899 punct ],5
R511 T903 T888 punct ", ",found
R512 T904 T905 amod further,analysis
R513 T905 T888 nsubj analysis,found
R514 T906 T905 prep of,analysis
R515 T907 T908 amod several,patients
R516 T908 T906 pobj patients,of
R517 T909 T888 dobj evidence,found
R518 T910 T911 mark that,improved
R519 T911 T909 acl improved,evidence
R520 T912 T913 compound amyloid,pathology
R521 T913 T911 nsubjpass pathology,improved
R522 T914 T913 punct ", ",pathology
R523 T915 T913 cc and,pathology
R524 T916 T917 prep to,function
R525 T917 T913 conj function,pathology
R526 T918 T919 det a,degree
R527 T919 T916 pobj degree,to
R528 T920 T919 amod lesser,degree
R529 T921 T917 amod cognitive,function
R530 T922 T911 punct ", ",improved
R531 T923 T911 auxpass was,improved
R532 T924 T911 prep in,improved
R533 T925 T924 pobj proportion,in
R534 T926 T925 prep to,proportion
R535 T927 T928 det the,patient
R536 T928 T929 poss patient,titer
R537 T929 T926 pobj titer,to
R538 T930 T928 case 's,patient
R539 T931 T929 prep of,titer
R540 T932 T933 npadvmod Aβ,specific
R541 T933 T935 amod specific,antibody
R542 T934 T933 punct -,specific
R543 T935 T931 pobj antibody,of
R544 T936 T937 punct [,7
R545 T937 T911 parataxis 7,improved
R546 T938 T937 nummod 6,7
R547 T939 T937 punct ",",7
R548 T940 T937 punct ],7
R549 T941 T888 punct .,found
R550 T943 T944 mark While,is
R551 T944 T947 advcl is,have
R552 T945 T946 det this,approach
R553 T946 T944 nsubj approach,is
R554 T948 T944 acomp promising,is
R555 T949 T947 punct ", ",have
R556 T950 T951 amod constant,exposure
R557 T951 T947 nsubj exposure,have
R558 T952 T951 prep to,exposure
R559 T953 T952 pobj antibodies,to
R560 T954 T955 dep that,recognize
R561 T955 T953 relcl recognize,antibodies
R562 T956 T957 det an,epitope
R563 T957 T955 dobj epitope,recognize
R564 T958 T959 advmod highly,enriched
R565 T959 T957 amod enriched,epitope
R566 T960 T959 prep in,enriched
R567 T961 T962 det the,brain
R568 T962 T960 pobj brain,in
R569 T963 T947 aux may,have
R570 T964 T965 amod unexpected,effects
R571 T965 T947 dobj effects,have
R572 T966 T965 compound side,effects
R573 T967 T968 dep that,limit
R574 T968 T965 relcl limit,effects
R575 T969 T968 aux will,limit
R576 T970 T971 poss its,use
R577 T971 T968 dobj use,limit
R578 T972 T973 amod long,term
R579 T973 T971 compound term,use
R580 T974 T973 punct -,term
R581 T975 T947 punct .,have
R582 T977 T978 det An,approach
R583 T978 T980 nsubj approach,seeks
R584 T979 T978 amod alternative,approach
R585 T981 T982 dep that,pursued
R586 T982 T978 relcl pursued,approach
R587 T983 T982 aux is,pursued
R588 T984 T982 auxpass being,pursued
R589 T985 T982 advmod actively,pursued
R590 T986 T982 prep for,pursued
R591 T987 T988 amod future,treatment
R592 T988 T986 pobj treatment,for
R593 T989 T988 prep of,treatment
R594 T990 T989 pobj AD,of
R595 T991 T992 aux to,lower
R596 T992 T980 xcomp lower,seeks
R597 T993 T994 compound Aβ,levels
R598 T994 T992 dobj levels,lower
R599 T995 T992 prep by,lower
R600 T996 T995 pcomp limiting,by
R601 T997 T998 poss its,production
R602 T998 T996 dobj production,limiting
R603 T999 T996 prep from,limiting
R604 T1000 T1001 det the,protein
R605 T1001 T999 pobj protein,from
R606 T1002 T1001 compound precursor,protein
R607 T1003 T1001 appos APP,protein
R608 T1004 T980 punct .,seeks
R609 T1006 T1007 compound Peptide,Aβ
R610 T1007 T1008 nsubjpass Aβ,released
R611 T1009 T1008 auxpass is,released
R612 T1010 T1008 prep from,released
R613 T1011 T1010 pobj APP,from
R614 T1012 T1008 agent by,released
R615 T1013 T1014 det the,action
R616 T1014 T1012 pobj action,by
R617 T1015 T1014 prep of,action
R618 T1016 T1017 nummod two,enzymes
R619 T1017 T1015 pobj enzymes,of
R620 T1018 T1017 punct ", ",enzymes
R621 T1019 T1020 det the,enzyme
R622 T1020 T1017 appos enzyme,enzymes
R623 T1021 T1022 compound β,APP
R624 T1022 T1024 npadvmod APP,cleaving
R625 T1023 T1022 punct -,APP
R626 T1024 T1020 amod cleaving,enzyme
R627 T1025 T1020 nummod 1,enzyme
R628 T1026 T1020 punct (,enzyme
R629 T1027 T1020 appos BACE1,enzyme
R630 T1028 T1020 punct ),enzyme
R631 T1029 T1020 cc and,enzyme
R632 T1030 T1031 punct γ,secretase
R633 T1031 T1020 conj secretase,enzyme
R634 T1032 T1031 punct -,secretase
R635 T1033 T1017 punct ", ",enzymes
R636 T1034 T1035 dep which,cleave
R637 T1035 T1017 relcl cleave,enzymes
R638 T1036 T1037 det the,holoprotein
R639 T1037 T1035 dobj holoprotein,cleave
R640 T1038 T1035 prep at,cleave
R641 T1039 T1040 det the,termini
R642 T1040 T1038 pobj termini,at
R643 T1041 T1040 nmod N,termini
R644 T1042 T1041 punct -,N
R645 T1043 T1041 cc and,N
R646 T1044 T1041 conj C,N
R647 T1045 T1040 punct -,termini
R648 T1046 T1040 prep of,termini
R649 T1047 T1046 pobj Aβ,of
R650 T1048 T1008 punct ", ",released
R651 T1049 T1008 advmod respectively,released
R652 T1050 T1008 punct .,released
R653 T1052 T1053 amod Several,inhibitors
R654 T1053 T1054 nsubjpass inhibitors,produced
R655 T1055 T1053 prep of,inhibitors
R656 T1056 T1057 punct γ,secretase
R657 T1057 T1055 pobj secretase,of
R658 T1058 T1057 punct -,secretase
R659 T1059 T1054 aux have,produced
R660 T1060 T1054 advmod already,produced
R661 T1061 T1054 auxpass been,produced
R662 T1062 T1063 punct [,9
R663 T1063 T1054 parataxis 9,produced
R664 T1064 T1063 nummod 8,9
R665 T1065 T1063 punct ",",9
R666 T1066 T1063 punct ],9
R667 T1067 T1054 punct ", ",produced
R668 T1068 T1054 cc and,produced
R669 T1069 T1070 amod small,inhibitors
R670 T1070 T1072 nsubjpass inhibitors,developed
R671 T1071 T1070 compound molecule,inhibitors
R672 T1072 T1054 conj developed,produced
R673 T1073 T1070 prep of,inhibitors
R674 T1074 T1075 compound β,APP
R675 T1075 T1077 npadvmod APP,cleaving
R676 T1076 T1075 punct -,APP
R677 T1077 T1078 amod cleaving,enzyme
R678 T1078 T1073 pobj enzyme,of
R679 T1079 T1078 nummod 1,enzyme
R680 T1080 T1072 aux are,developed
R681 T1081 T1072 advmod currently,developed
R682 T1082 T1072 auxpass being,developed
R683 T1083 T1084 punct [,11
R684 T1084 T1072 parataxis 11,developed
R685 T1085 T1084 nummod 10,11
R686 T1086 T1084 punct ",",11
R687 T1087 T1084 punct ],11
R688 T1088 T1072 punct .,developed
R689 T1090 T1091 det The,effectiveness
R690 T1091 T1095 nsubjpass effectiveness,reported
R691 T1092 T1093 amod long,term
R692 T1093 T1091 compound term,effectiveness
R693 T1094 T1093 punct -,term
R694 T1096 T1091 prep of,effectiveness
R695 T1097 T1098 det this,approach
R696 T1098 T1096 pobj approach,of
R697 T1099 T1091 prep in,effectiveness
R698 T1100 T1101 preconj either,humans
R699 T1101 T1099 pobj humans,in
R700 T1102 T1101 cc or,humans
R701 T1103 T1104 compound model,systems
R702 T1104 T1101 conj systems,humans
R703 T1105 T1095 punct ", ",reported
R704 T1106 T1095 advmod however,reported
R705 T1107 T1095 punct ", ",reported
R706 T1108 T1095 aux has,reported
R707 T1109 T1095 neg not,reported
R708 T1110 T1095 auxpass been,reported
R709 T1111 T1095 punct .,reported
R710 T1113 T1114 mark Although,prevent
R711 T1114 T1125 advcl prevent,known
R712 T1115 T1114 nsubj loss,prevent
R713 T1116 T1115 prep of,loss
R714 T1117 T1118 compound β,APP
R715 T1118 T1120 npadvmod APP,cleaving
R716 T1119 T1118 punct -,APP
R717 T1120 T1121 amod cleaving,function
R718 T1121 T1116 pobj function,of
R719 T1122 T1121 nmod enzyme,function
R720 T1123 T1122 nummod 1,enzyme
R721 T1124 T1114 aux can,prevent
R722 T1126 T1127 det the,development
R723 T1127 T1114 dobj development,prevent
R724 T1128 T1127 prep of,development
R725 T1129 T1128 pobj plaques,of
R726 T1130 T1114 prep in,prevent
R727 T1131 T1132 amod transgenic,models
R728 T1132 T1130 pobj models,in
R729 T1133 T1132 compound mouse,models
R730 T1134 T1132 prep for,models
R731 T1135 T1134 pobj AD,for
R732 T1136 T1137 punct (,F.
R733 T1137 T1114 meta F.,prevent
R734 T1138 T1137 nmod Laird,F.
R735 T1139 T1137 punct ", ",F.
R736 T1140 T1137 nmod H.,F.
R737 T1141 T1137 nmod Cai,F.
R738 T1142 T1137 punct ", ",F.
R739 T1143 T1137 nmod P.,F.
R740 T1144 T1137 nmod C.,F.
R741 T1145 T1137 nmod Wong,F.
R742 T1146 T1137 punct ", ",F.
R743 T1147 T1137 amod personal,F.
R744 T1148 T1137 nmod communication,F.
R745 T1149 T1137 punct ),F.
R746 T1150 T1125 punct ", ",known
R747 T1151 T1125 nsubjpass it,known
R748 T1152 T1125 auxpass is,known
R749 T1153 T1125 neg not,known
R750 T1154 T1155 mark whether,clear
R751 T1155 T1125 ccomp clear,known
R752 T1156 T1157 det the,brain
R753 T1157 T1155 nsubj brain,clear
R754 T1158 T1155 aux can,clear
R755 T1159 T1160 amod pre-existing,deposits
R756 T1160 T1155 dobj deposits,clear
R757 T1161 T1160 compound amyloid,deposits
R758 T1162 T1163 mark once,suppressed
R759 T1163 T1155 advcl suppressed,clear
R760 T1164 T1163 nsubjpass production,suppressed
R761 T1165 T1164 prep of,production
R762 T1166 T1165 pobj Aβ,of
R763 T1167 T1163 aux has,suppressed
R764 T1168 T1163 auxpass been,suppressed
R765 T1169 T1125 punct .,known
R766 T1171 T1172 advmod Clearly,examined
R767 T1173 T1172 punct ", ",examined
R768 T1174 T1175 det the,approach
R769 T1175 T1172 nsubjpass approach,examined
R770 T1176 T1177 npadvmod amyloid,lowering
R771 T1177 T1175 amod lowering,approach
R772 T1178 T1177 punct -,lowering
R773 T1179 T1172 aux should,examined
R774 T1180 T1172 auxpass be,examined
R775 T1181 T1172 advmod rigorously,examined
R776 T1182 T1172 prep in,examined
R777 T1183 T1184 compound animal,models
R778 T1184 T1182 pobj models,in
R779 T1185 T1186 mark before,tested
R780 T1186 T1172 advcl tested,examined
R781 T1187 T1188 det these,reagents
R782 T1188 T1186 nsubjpass reagents,tested
R783 T1189 T1186 auxpass are,tested
R784 T1190 T1186 prep in,tested
R785 T1191 T1190 pobj patients,in
R786 T1192 T1172 punct .,examined
R787 T1194 T1195 advmod However,are
R788 T1196 T1195 punct ", ",are
R789 T1197 T1198 det the,inhibitors
R790 T1198 T1195 nsubj inhibitors,are
R791 T1199 T1198 amod chemical,inhibitors
R792 T1200 T1198 compound secretase,inhibitors
R793 T1201 T1202 advmod most,likely
R794 T1202 T1198 amod likely,inhibitors
R795 T1203 T1204 aux to,reach
R796 T1204 T1202 xcomp reach,likely
R797 T1205 T1206 amod human,trials
R798 T1206 T1204 dobj trials,reach
R799 T1207 T1195 advmod still,are
R800 T1208 T1195 prep in,are
R801 T1209 T1208 pobj development,in
R802 T1210 T1195 punct .,are
R803 T1212 T1213 advmod Therefore,developed
R804 T1214 T1213 punct ", ",developed
R805 T1215 T1213 nsubj we,developed
R806 T1216 T1217 det a,model
R807 T1217 T1213 dobj model,developed
R808 T1218 T1217 compound mouse,model
R809 T1219 T1217 prep of,model
R810 T1220 T1221 compound Alzheimer,type
R811 T1221 T1223 compound type,amyloid
R812 T1222 T1221 punct -,type
R813 T1223 T1219 pobj amyloid,of
R814 T1224 T1225 dep that,expresses
R815 T1225 T1223 relcl expresses,amyloid
R816 T1226 T1227 det a,transgene
R817 T1227 T1225 dobj transgene,expresses
R818 T1228 T1227 amod controllable,transgene
R819 T1229 T1227 compound APP,transgene
R820 T1230 T1213 punct .,developed
R821 T1232 T1233 det This,system
R822 T1233 T1234 nsubjpass system,regulated
R823 T1235 T1233 punct ", ",system
R824 T1236 T1237 advmod commonly,known
R825 T1237 T1233 acl known,system
R826 T1238 T1237 prep as,known
R827 T1239 T1240 det the,system
R828 T1240 T1238 pobj system,as
R829 T1241 T1242 compound tet,off
R830 T1242 T1240 compound off,system
R831 T1243 T1242 punct -,off
R832 T1244 T1234 punct ", ",regulated
R833 T1245 T1234 aux can,regulated
R834 T1246 T1234 auxpass be,regulated
R835 T1247 T1234 agent by,regulated
R836 T1248 T1247 pobj analogs,by
R837 T1249 T1248 prep of,analogs
R838 T1250 T1249 pobj tetracycline,of
R839 T1251 T1250 acl administered,tetracycline
R840 T1252 T1251 prep in,administered
R841 T1253 T1252 pobj food,in
R842 T1254 T1253 cc or,food
R843 T1255 T1253 conj water,food
R844 T1256 T1257 punct [,13
R845 T1257 T1234 parataxis 13,regulated
R846 T1258 T1257 nummod 12,13
R847 T1259 T1257 punct ",",13
R848 T1260 T1257 punct ],13
R849 T1261 T1234 punct .,regulated
R850 T1263 T1264 det The,levels
R851 T1264 T1267 nsubj levels,allowed
R852 T1265 T1264 amod strong,levels
R853 T1266 T1264 compound expression,levels
R854 T1268 T1264 acl produced,levels
R855 T1269 T1268 prep with,produced
R856 T1270 T1271 det the,vectors
R857 T1271 T1269 pobj vectors,with
R858 T1272 T1273 compound tet,off
R859 T1273 T1271 compound off,vectors
R860 T1274 T1273 punct -,off
R861 T1275 T1271 punct ", ",vectors
R862 T1276 T1271 acl combined,vectors
R863 T1277 T1276 prep with,combined
R864 T1278 T1279 det the,ability
R865 T1279 T1277 pobj ability,with
R866 T1280 T1281 aux to,reduce
R867 T1281 T1279 acl reduce,ability
R868 T1282 T1283 det this,expression
R869 T1283 T1281 dobj expression,reduce
R870 T1284 T1281 prep by,reduce
R871 T1285 T1286 amod several,orders
R872 T1286 T1284 pobj orders,by
R873 T1287 T1286 prep of,orders
R874 T1288 T1287 pobj magnitude,of
R875 T1289 T1281 prep with,reduce
R876 T1290 T1289 pobj tetracycline,with
R877 T1291 T1292 punct [,14
R878 T1292 T1281 parataxis 14,reduce
R879 T1293 T1292 punct ],14
R880 T1294 T1267 punct ", ",allowed
R881 T1295 T1267 prep for,allowed
R882 T1296 T1297 det a,test
R883 T1297 T1295 pobj test,for
R884 T1298 T1297 amod stringent,test
R885 T1299 T1297 prep of,test
R886 T1300 T1301 advmod how,impact
R887 T1301 T1299 pobj impact,of
R888 T1302 T1303 det a,inhibitor
R889 T1303 T1301 nsubj inhibitor,impact
R890 T1304 T1305 advmod highly,effective
R891 T1305 T1303 amod effective,inhibitor
R892 T1306 T1303 amod pharmaceutical,inhibitor
R893 T1307 T1303 prep of,inhibitor
R894 T1308 T1309 compound Aβ,production
R895 T1309 T1307 pobj production,of
R896 T1310 T1301 aux would,impact
R897 T1311 T1312 det the,progression
R898 T1312 T1301 dobj progression,impact
R899 T1313 T1312 prep of,progression
R900 T1314 T1315 compound amyloid,pathology
R901 T1315 T1313 pobj pathology,of
R902 T1316 T1301 cc and,impact
R903 T1317 T1318 mark whether,be
R904 T1318 T1301 conj be,impact
R905 T1319 T1318 nsubj reversal,be
R906 T1320 T1319 prep of,reversal
R907 T1321 T1322 det these,lesions
R908 T1322 T1320 pobj lesions,of
R909 T1323 T1318 aux might,be
R910 T1324 T1318 acomp possible,be
R911 T1325 T1318 prep following,be
R912 T1326 T1325 prep such,following
R913 T1327 T1326 pobj treatment,such
R914 T1328 T1267 punct .,allowed